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ABSTRACT 
Introductions: This study was designed to determine the demographic 
pattern, incidence, clinical features and management outcome of 
gestational trophoblastic disease (GTD) in Patan Hospital. 
 
Methods: This is a cross sectional study conducted at Patan Hospital from 
April 13, 2008 to April 12, 2013. Medical record of cases diagnosed as GTD 
were retrieved from the record section for review. The age, parity, 
estimated gestational age at the time of evacuation, presence or absence 
of vaginal bleeding, uterine size in relation to gestational age, 
ultrasonogram report and urinary beta human chorionic gonadotropin 
level, histopathology findings, modalities of treatment and outcomes 
were analyzed. 
 
Results: There was total of 41,543 deliveries during five year study period 
and 54 GTD on histopathology. Among the 54 GTD, 40 (74%) were molar 
pregnancy, 8 (14.4%) invasive mole and 6 (11%) choriocarcinoma. The 
frequency of GTD was 1 per 769 pregnancies. The age of the women with 
GTD ranged from 15 -50 years. Half of the cases were below 25 years.  
Most of the women presented between 8-12 weeks of gestation and 
below third gravida. Amenorrhea with vaginal bleeding was seen in 49 
(90%) patients. 
 
Conclusions: The most common GTD observed in this study was molar 
pregnancy. Vaginal bleeding and lower abdominal pain were the most 
common complaints at presentation. 
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INTRODUCTIONS 
 
Gestational trophoblastic disease (GTD) covers a 
range of pregnancy-related disorders. This includes 
complete and partial hydatiform mole which are 
the premalignant form; invasive mole and 
choriocarcinoma which are the malignant form and 
lastly the placental site trophoblastic tumor which 
is rare. The latter three conditions can progress, 
invade, metastasize, and lead to death if left 
untreated or not well treated. These conditions are 
collectively termed as “gestational trophoblastic 
neoplasia” (GTN).  
 
There is wide variation in the incidence of GTD 
across the world.1 In the Asian countries the 
incidence is higher than in the Western countries.2 
This study is carried out to determine the 
demographic pattern, frequency, clinical features 
and management outcome of GTD at Patan 





This was a cross sectional study conducted at 
Patan Hospital after the ethical clearance from the 
Institutional Review Committee of Patan Academy 
of Health Sciences. All the cases diagnosed, 
clinically or by histopathological report, as GTD 
during the period of April 13, 2008 to April 12, 
2013 were retrieved from the medical record 
section for review. The following variables were 
analyzed: age, parity, estimated gestational age at 
the time of evacuation, presence or absence of 
vaginal bleeding, uterine size in relation to 
gestational age, ultra-sonogram report and urinary 
beta human chorionic gonadotropin (βhCG) level, 
histopathology report, modalities of treatment, 






During the five years study period there were 
41,543 deliveries. Out of this, 58 were suspected 
cases of GTD by ultrasound and clinical 
presentation. Four cases turned out to be product 
of conception on histopathology report, and were 
excluded from study. Therefore, the total number 
of confirmed GTD was 54, 1 per 769 pregnancies. 
Twenty women were in age group 20-25 years 
(Table 1) and amenorrhoea with vaginal bleeding 
was most common presentation in 21 women 
(Table 2).  
 
Primi gravida were 19 (35.2%), gravida one to four 
were 28 (51.8%) and 7 (13%) were grand 
multipara. Patient presenting between gestational 
age of 8 to 12 weeks were 44 (81%), 14 to 18 
weeks were five (9%) and those presenting at 19 to 
24 weeks were five (9%). 
 
Table 1. Age distribution of patients with GTD 
Gestational trophoblastic disease (GTD)  
 
 
Table 2. Clinical feature of GTD at presentation  
Symptoms  No. % 
Vaginal bleeding 19 35.2 
Amenorrhoea  09 16.7 
Amenorrhoea with bleeding  21 38.9 
Passage of vesicles 01 1.8 
Shock  01 1.8 
USG diagnosed 03 5.6 
Total 54 100 
 
The uterine size at the time of presentation was 
larger than gestational age in 27 (50%), smaller in 7 
(13%) and corresponded to the gestational age in 
20 (37%).  
All of the cases had suction evacuation and sent 
for histopathology examination. Fifteen cases 
(28%) required blood transfusion. Among 54 GTD, 
40 were molar pregnancy, six choriocarcinoma and 
eight invasive mole (Table 3). 
 
Table 3. The GTD according to histopathology report 
Type No. % 
Hydatidiform mole 40 74.1 
Choriocarcinoma 06 11.1 
Invasive mole 08 14.8 
Placental site trophoblastic 
tumor 
00 00 
Total 54 100 
 
Age  No. % 
15-19   7 13 
20-25 20 37 
26-30 12 22.2 
31-35   05 9.3 
36-40   04 7.4 
41-45   01 1.8 
46-50   05 9.3 
Total 54 100 
4  
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Out of total 54 GTD patients, 25 (46.2%) did not 
require further intervention after evacuation, 22 
(40.7%) required chemotherapy and seven (12.9%) 
total abdominal hysterectomy. Repeat evacuation 
due to retained molar tissue was done in 11 (20%) 
patients. Ten patients (18.5%) were cured with low 
risk chemotherapy regime and 12 (22.2%) with 
high risk chemotherapy regime. Out of 12 high risk 
chemotherapy regime, ten (18.5%) were 
conversion from low risk regimen after treatment 
failure. Low risk regime consisted of Methetrexate 
and Folinic Acid and high-risk regime consisted of 






This study had 1.3 GTD per 1000 deliveries. 
Different hospitals in Nepal have reported higher 
incidence of 2.8 to 5.1 per 1000 deliveries whereas 
in United States it was only 0.4 per 1000 
deliveries.3,4 The incidence of hydatidiform mole 
was 1 in 1039 deliveries. Japan has reported 
hydatidiform mole complicating 2 of every 1000 
pregnancies, higher than in our study, whereas 
much lower in the United States at one per 1000.5,6 
The incidence of choriocarcinoma in this study was 
1 in 6924 and one of the leading malignant tumors 
in women in Africa, but less common the United 
states at 1 in 30,000 pregnancies.7,8 
 
This study also found high incidence of GTD among 
younger age group below 25 years. Most studies 
show higher risk in older than 35.7 Acharya’s study 
also showed 87.5% of molar pregnancy was among 
young women below 35 years.9 In Riadh’s series, 
the maternal age factor was identified as an 
important risk factor and women older than 40 
years had substantially higher incidence rates.10 
 
Many studies do not show clear relation between 
gravidity, parity and GTD.11  But Thapa’s study 
found higher incidence of mole among 
primigravidae (36.7%) and Elpo in Nigeria  reported 
that parity four and above in particular adds to the 
risk.11,12 In this study we found that the incidence 
of GTD (76%) was more in parity two and less. 
 
Some of the most typical clinical features of molar 
pregnancy are vaginal bleeding, uterine size larger 
than date, early onset of preeclampsia, anemia, 
theca lutein cysts and hyperemesis gravidarum. 
But there are cases where there is irregular vaginal 
bleeding lasting for a few weeks to months and the 
flow varying from spotting to profuse bleeding.13 
Vaginal bleeding is a common symptom, being 
present about 70 – 97% of the patients in most 
series.14 In our study also, vaginal bleeding with 
amenorrhoea was the most common complaint 
followed by vaginal bleeding alone. In recent 
period, complication of GTD such as early onset of 
pre-eclampsia, pulmonary embolism, severe 
anemia and large lutein cyst are less commonly 
encountered because of early diagnosis by 
sonography. 
 
The uterus was larger than date in 50% of the 
cases in 
this study, consistent with Burger’s and Thapa’s 
study.13,11 Felembam et al reported that only 28% 
of their cases had uterus larger than date probably 
because of early detection by ultrasound.15 
 
In this study suction evacuation was done in all the 
cases. Follow up was done initially by weekly 
serum βhCG until it returned to normal. After 
which it was done two weekly, then four weekly 
for six months. The GTN was diagnosed when 
there was a plateau of βhCG value, that is 1) four 
values lasting over a period of three weeks or 
longer, 2) when there was a rise for three 
consecutive weeks or longer, 3) when remained 
elevated for six months or more, 4) when there 
was a histological diagnosis of choriocarcinoma.  
 
Methotrexate with folinic acid rescue was given for 
low risk GTN which is still the most effective single 
agent in the treatment of low risk patients. For 
high risk patients, EMA-CO (etoposide, 
methotrexate, actinomycin, cyclophosphamide 





In this study molar pregnancy was the most 
common GTD occurring more in the age group less 
than 25 years and in parity two or less. The most 
common presentation were amenorrhoea with 
vaginal bleeding and more than half of the patient 
had uterine size larger than date. The most 
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